MedPath
EMA Product

Aflunov

Product approved by European Medicines Agency (EU)

Basic Information

Aflunov

Regulatory Information

November 4, 2024

Active Substances Detail

influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: A/turkey/Turkey/1/05 (H5N1)-like strain (NIBRG-23)

Detailed Information

Therapeutic Indication

### Therapeutic indication Active immunisation against H5N1 subtype of Influenza A virus in individuals 6 months of age and above. Aflunov should be used in accordance with official recommendations.

Overview Summary

Aflunov is a vaccine used in adults and children above the age of 6 months to protect against flu caused by the H5N1 (‘bird flu’) strain of the influenza A virus. Aflunov contains parts of influenza (flu) viruses that have been inactivated (killed). Aflunov contains parts from a flu strain called A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23). (clade 2.2.1).

© Copyright 2025. All Rights Reserved by MedPath